Newsroom

CSRxP Statement on HHS OIG Part D Spending Report

Today, the Office of the Inspector General at the Department of Health and Human Services (OIG) released a report entitled, “Increases in Reimbursement for Brand-Name Drugs […]

Read more

CSRxP Applauds FDA’s Focus on REMS Abuses

The Campaign for Sustainable Rx Pricing released the following statement attributable to CSRxP spokesman Will Holley: “Today’s FDA guidance is a step in the right direction […]

Read more

CSRxP Applauds FDA’s Transparency on Brand “Gaming” Tactics

The Campaign for Sustainable Rx Pricing released the following statement attributable to CSRxP spokesman Will Holley: “We applaud the Administration’s focus on out-of-control prescription drug prices […]

Read more

CSRxP on President Trump’s Remarks on Drug Prices

The Campaign for Sustainable Rx Pricing released the following statement attributable to CSRxP Executive Director Lauren Aronson: “We applaud the President for his focus on this […]

Read more